News
ORKA
11.18
-2.19%
-0.25
Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
TipRanks · 5d ago
Weekly Report: what happened at ORKA last week (0203-0207)?
Weekly Report · 5d ago
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
Benzinga · 02/07 12:32
Oruka Therapeutics Positioned for Growth with Strategic Licensing and Promising IL-17A/F Inhibitor Development
TipRanks · 02/07 11:35
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/05 12:05
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 02/04 14:15
Oruka Therapeutics Price Target Announced at $20.00/Share by Wolfe Research
Dow Jones · 02/04 13:30
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 02/04 13:17
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/04 12:05
Oruka Therapeutics initiated with an Outperform at Wolfe Research
TipRanks · 02/04 01:01
Weekly Report: what happened at ORKA last week (0127-0131)?
Weekly Report · 02/03 12:13
Oruka Therapeutics Inc <ORKA.OQ> expected to post a loss of 68 cents a share - Earnings Preview
Reuters · 01/28 21:09
Weekly Report: what happened at ORKA last week (0120-0124)?
Weekly Report · 01/27 12:18
Weekly Report: what happened at ORKA last week (0113-0117)?
Weekly Report · 01/20 12:05
Leerink Partners Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 01/20 07:37
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 01/15 13:52
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/15 10:10
Weekly Report: what happened at ORKA last week (0106-0110)?
Weekly Report · 01/13 12:07
Weekly Report: what happened at ORKA last week (1230-0103)?
Weekly Report · 01/06 12:18
More
Webull provides a variety of real-time ORKA stock news. You can receive the latest news about Oruka Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORKA
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).